Quarterly report pursuant to Section 13 or 15(d)

Term Debt (Details)

Term Debt (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 02, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 13, 2019
Debt Disclosure [Abstract]        
Term debt       $ 8,000
Term debt, description Principal payments will commence July 1, 2022 and continuing for 24 consecutive months thereafter. The Company may prepay all, but not less than all, of the outstanding principal balance of the Term Debt subject to prepayment premium of $240, plus all other sums, if any, that shall have become due and payable. The Term Debt of $8,000 bears an interest rate equal to the greater of (i) one-half of one percent (0.50%) above the Prime Rate and (ii) five and one-half percent (5.50%). At March 31, 2021, the interest rate was 5.50%. The Term Debt is collateralized by substantially all assets of the Company. Additionally, the Company has pledged 65% of the outstanding capital stock in the Company’s foreign subsidiary, Motus GI Medical Technologies, Ltd., to collateralize the Term Debt.    
Debt issuance costs   $ 50    
Debt issuance costs was amortized to interest expense   $ 2 $ 19  
Interest rate   5.69%    
Bank least   $ 10,000